The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).

The control group will not receive hydroxychloroquine.

COVID-19

Hydroxychloroquine

The control group will not receive hydroxychloroquine

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Number patients developing severe infection or death

Rambam Health Care Campus

Rabin Medical Center

30 Patients will be treated with combined DFP and deferasirox.

Patients will be treated for 6 days with a combination of deferoxamine and DFP

Beta-thalassemia Major

Sickle Cell Disease

Iron Hemosiderosis

Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).
Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.
Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.
Other Name: ICL670

DFP (ferriprox) and deferasirox (ICL 670)

Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.
Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days

DFP, DFO

Pediatric Hematology clinic, Ain Shams University

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload

• The primary outcome measure is to measure the change in serum ferritin level from baseline in the 2 combination therapy.

• The secondary outcome measure is to determine the number of patients who will develop adverse reactions upon administering the drugs in combination.

digoxin/fever

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

科学に裏打ちされた最も完全な薬草データベース